ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
QP12-17 Prior Authorization/Pre-Approval Forms Specific to Select Medical Policies
တၢ်ရဲၣ်တၢ်ကျဲၤစးထီၣ်မူ၀ဲ အမုၢ်နံၤမုၢ်သီ- လါမ့ၤ 31, 2017
တၢ်ဃုသ့ၣ်ညါတၢ်အစၢ
တၢ်ပာ်ဖျါ 3021 - 3030 လၢ 3669 အစၢတဖၣ်အကျါ
ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
QP44-17 New Pre-Authorization Form for Botulinum Toxin for Commercial Products
တၢ်ရဲၣ်တၢ်ကျဲၤစးထီၣ်မူ၀ဲအမုၢ်နံၤမုၢ်သီ- လါဒံၣ်စဲဘၢၣ် 05, 2017
ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
QP31-17 New Pre-Authorization Form for Infliximab
တၢ်ရဲၣ်တၢ်ကျဲၤစးထီၣ်မူ၀ဲအမုၢ်နံၤမုၢ်သီ- လါအီးကထိဘၢၣ် 05, 2017
ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
QP37-16 Difference in Operating Systems Identified - GY Modifier
တၢ်ရဲၣ်တၢ်ကျဲၤစးထီၣ်မူ၀ဲအမုၢ်နံၤမုၢ်သီ- လါဒံၣ်စဲဘၢၣ် 09, 2016
ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
QP11-16 New BlueRide Email Notification Option for SNF
တၢ်ရဲၣ်တၢ်ကျဲၤစးထီၣ်မူ၀ဲ အမုၢ်နံၤမုၢ်သီ- လါမ့ၤ 04, 2016
ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
QP17-16 Claims with Attachments
တၢ်ရဲၣ်တၢ်ကျဲၤစးထီၣ်မူ၀ဲ အမုၢ်နံၤမုၢ်သီ- လါယူၤလံ 26, 2016
ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
QP24-16 Post-Cataract Care Units Billing
တၢ်ရဲၣ်တၢ်ကျဲၤစးထီၣ်မူ၀ဲ အမုၢ်နံၤမုၢ်သီ- လါစဲးပတ့ဘၢၣ် 08, 2016
ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
QP7-16 Inquiring and Updating Pre-Admission Notification Submissions on the Availity Web Portal
တၢ်ရဲၣ်တၢ်ကျဲၤစးထီၣ်မူ၀ဲအမုၢ်နံၤမုၢ်သီ- လါမာ်ရှး 30, 2016
ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
QP34-18 Pharmacy Benefit Update - New Drug-Related Prior Authorization (PA) with Quantity Limit (QL) Criteria: Uric Acid Transport 1 (URAT1) Inhibitor
တၢ်ရဲၣ်တၢ်ကျဲၤစးထီၣ်မူ၀ဲ အမုၢ်နံၤမုၢ်သီ- လါမ့ၤ 15, 2018
ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
QP42-16 Pharmacy Step Therapy Program Name Change for Anticonvulsant Agents and Update on Drugs Subject to This Step Therapy Program
တၢ်ရဲၣ်တၢ်ကျဲၤစးထီၣ်မူ၀ဲအမုၢ်နံၤမုၢ်သီ- လါဒံၣ်စဲဘၢၣ် 15, 2016